Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1-Reference-Cited by-同舟云学术

Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1

Published:2021-07-12 Issue:15 Volume:95 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Ao Zhujun¹,Wang Lijun¹,Azizi Hiva²,Olukitibi Titus Abiola¹,Kobinger Gary²^ORCID,Yao Xiaojian¹^ORCID

Affiliation:

1. Laboratory of Molecular Human Retrovirology, Department of Medical Microbiology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada

2. Centre de Recherche en Infectiologie de l'Université Laval/Centre Hospitalier de l'Université Laval, Québec, Quebec, Canada

Abstract

Currently, there are more than 38.5 million reported cases of HIV globally. To date, there is no approved vaccine for HIV-1 infection.

Funder

Gouvernement du Canada | Canadian Institutes of Health Research

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/JVI.02368-20

Reference67 articles.